Literature DB >> 15626896

Pancreatic autoantibodies in inflammatory bowel disease.

Sofie Joossens1, Severine Vermeire, Kristel Van Steen, Godelieve Godefridis, Greet Claessens, Marie Pierik, Robert Vlietinck, Raymond Aerts, Paul Rutgeerts, Xavier Bossuyt.   

Abstract

BACKGROUND: Autoantibodies against exocrine pancreas (PABs) have been reported to be specific for Crohn's disease (CD), albeit at a low prevalence (30%). We studied PABs in patients with inflammatory bowel disease (IBD), unaffected family members, and control subjects.
METHODS: A Belgian study cohort of 575 subjects, including 289 IBD patients (CD, 169 patients; ulcerative colitis [UC], 120 patients), 108 unaffected first-degree relatives, 78 subjects with non-IBD gastrointestinal disorders (gastrointestinal control subjects [GIcos]), and 100 healthy control subjects (Hcos), were tested for PAB by a standardized indirect immunofluorescence method.
RESULTS: The prevalence of PABs in this study cohort was 32% for CD, 23.3% for UC, and 22.2% for their unaffected family members (all P < 0.001), compared with 1.3% for GIcos and 0% for Hcos. Two staining patterns could be observed: an intracellular pattern (IC); and an extracellular pattern (EC). The EC was significantly more prevalent in CD patients compared with UC patients (P = 0.014), and higher titers of this pattern were found in CD patients (P = 0.01). Both PAB patterns were negatively associated with stricturing disease behavior of CD (P = 0.021). The IC was associated with familial CD (P = 0.0009) and familial UC (P = 0.0003).
CONCLUSIONS: The prevalence of PAB found in CD patients in this study was similar to that cited in previous reports. In contrast to these reports, we also found an increased prevalence of PABs in patients with UC and in unaffected first-degree relatives of IBD patients. We observed two main staining patterns, both of which were present in IBD and were associated with specific phenotypes of the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15626896     DOI: 10.1097/00054725-200411000-00012

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  16 in total

Review 1.  Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.

Authors:  Anet A Soubières; Andrew Poullis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 2.  Relevance of serologic studies in inflammatory bowel disease.

Authors:  Gwenola Vernier; Boualem Sendid; Daniel Poulain; Jean-Frédéric Colombel
Journal:  Curr Gastroenterol Rep       Date:  2004-12

3.  Pancreatic autoantibodies in Greek patients with inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Dimitrios Drygiannakis; Konstantinos Karmiris; Ioannis Drygiannakis; Sokratis Makreas; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

4.  Hepatopancreatobiliary manifestations of inflammatory bowel disease.

Authors:  Kazuhiko Nakamura; Tetsuhide Ito; Kazuhiro Kotoh; Eikichi Ihara; Haruei Ogino; Tsutomu Iwasa; Yoshimasa Tanaka; Yoichiro Iboshi; Ryoichi Takayanagi
Journal:  Clin J Gastroenterol       Date:  2012-01-06

Review 5.  Extraintestinal manifestations and complications in inflammatory bowel diseases.

Authors:  Katja S Rothfuss; Eduard F Stange; Klaus R Herrlinger
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

Review 6.  Laboratory markers in ulcerative colitis: Current insights and future advances.

Authors:  Michele Cioffi; Antonella De Rosa; Rosalba Serao; Ilaria Picone; Maria Teresa Vietri
Journal:  World J Gastrointest Pathophysiol       Date:  2015-02-15

7.  Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives.

Authors:  Huseyin Demirsoy; Kamil Ozdil; Ozdal Ersoy; Besir Kesici; Cetin Karaca; Canan Alkim; Nihat Akbayir; Levent Kamil Erdem; Mehmet Derya Onuk; Hulya Tugrul Beyzadeoglu
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

Review 8.  New serological markers in pediatric patients with inflammatory bowel disease.

Authors:  Márta Kovács; Katalin Eszter Müller; Mária Papp; Péter László Lakatos; Mihály Csöndes; Gábor Veres
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

9.  Humoral immune responses of type 1 diabetes patients to Mycobacterium avium subsp. paratuberculosis lend support to the infectious trigger hypothesis.

Authors:  Leonardo A Sechi; Valentina Rosu; Adolfo Pacifico; Giovanni Fadda; Niyaz Ahmed; Stefania Zanetti
Journal:  Clin Vaccine Immunol       Date:  2007-12-12

10.  Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease.

Authors:  Liesbet Henckaerts; Marie Pierik; Marie Joossens; Marc Ferrante; Paul Rutgeerts; Séverine Vermeire
Journal:  Gut       Date:  2007-06-26       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.